Results Of Pradaxa Lawsuits Bring Encouragement To Plaintiffs Involved In Mounting Xarelto Lawsuits

March 31, 2016 – – BloodThinnerHelp.com reports on substantial similarities discovered between Xarelto and Pradaxa lawsuits, which help to bring encouragement to current Xarelto lawsuit plaintiffs as they await early 2017 bellwether trials. Xarelto lawsuit numbers appear to be continually increasing. Today, complaints which were federally-filed have been transferred and consolidated to a single court by the U.S. Judicial Panel on Multidistrict Litigation, forming MDL No. 2592. These lawsuits reportedly now number more than 2,800, and they are not alone. Another group of more than 600 Xarelto lawsuits has been consolidated by the Court of Common Pleas in Philadelphia, Pennsylvania to form a mass tort program.

Xarelto lawsuits consolidated in the MDL located in Eastern Louisiana and are currently being overseen by the Honorable Judge Eldon Fallon. All complaints share strikingly similar allegations against defendants Bayer AG and Janssen Pharmaceuticals, (a division of Johnson & Johnson).

Xarelto was approved by the U.S. Food and Drug Administration and was released to market in 2011. The drug is a new-generation blood thinner and was very popular, as it provided patients dependent upon blood thinners with freedoms that traditional blood thinners had been unable to. Xarelto was developed and approved to treat patients recovering from hip and knee replacement surgeries, pulmonary embolism, deep vein thrombosis, or atrial fibrillation.

Pradaxa is a similar new-generation anticoagulant drug, which was marketed by Boehringer Ingelheim in October of 2010. Like Xarelto, it did not take long after the blood thinner’s initial market release for it to become the topic of more than 3,500 adverse event reports to the FDA. More than 750 of these FDA adverse event reports detailed fatalities which were reportedly experienced by patients using the drug. Within a short time, Pradaxa became the subject of over 4,000 lawsuits, and plaintiffs filing the lawsuits were anxiously awaiting trial, hoping for what they believed to be justice. The evening before the trial was scheduled to take place, however, defendant Boehringer Ingelheim chose to settle the lawsuits by paying $650 million to the involved plaintiffs.

Today, Xarelto lawsuit plaintiffs look to this past settlement with many similarities and find encouragement that their current pursuits will bring them what they deem to be justice as the trial dates approach. These lawsuits continue to grow in number and are currently scheduled for bellwether trial hearings in early 2017.

As thousands of Xarelto lawsuit plaintiffs await further legal action, Attorney Joseph Osborne is working to help ensure that others who believe that they were negatively affected by using Xarelto will be given an opportunity to investigate their legal rights in the matter. Affected individuals may be entitled to legal action and significant compensation. To assist those needing it, Attorney Osborne is offering complimentary Xarelto consultations for involved parties at this time.

To ask questions concerning Xarelto lawsuits, or to request additional information, please contact Attorney Joseph Osborne by calling (866) 425-8902.

###

Contact BloodThinnerHelp.com:

Joseph Osborne
866-425-8902
Mizner Park
433 Plaza Real Blvd., Ste. 271
Boca Raton, FL 33432

ReleaseID: 60009003